<?xml version='1.0' encoding='utf-8'?>
<document id="12064567"><sentence text="Clinical pharmacology of bivalirudin."><entity charOffset="25-36" id="DDI-PubMed.12064567.s1.e0" text="bivalirudin" /></sentence><sentence text="Much progress has been made in understanding and treating acute coronary syndromes" /><sentence text=" For patients undergoing percutaneous transluminal coronary angioplasty, anticoagulant therapy during the procedure must strike a balance between providing sufficient anticoagulation to prevent thrombus formation and ischemic complications while averting hemorrhagic complications" /><sentence text=" Bivalirudin, a thrombin-specific anticoagulant, is the only anticoagulant that reduces both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI)"><entity charOffset="1-12" id="DDI-PubMed.12064567.s4.e0" text="Bivalirudin" /></sentence><sentence text=" Bivalirudin is easy to use, provides predictable anticoagulation, inactivates both free and clot-bound thrombin, and blocks thrombin-mediated platelet activation and aggregation"><entity charOffset="1-12" id="DDI-PubMed.12064567.s5.e0" text="Bivalirudin" /></sentence><sentence text=" Drug-drug interaction studies have found no clinically relevant interactions between bivalirudin and ticlopidine, abciximab, tirofiban, or eptifibatide"><entity charOffset="86-97" id="DDI-PubMed.12064567.s6.e0" text="bivalirudin" /><entity charOffset="102-113" id="DDI-PubMed.12064567.s6.e1" text="ticlopidine" /><entity charOffset="115-124" id="DDI-PubMed.12064567.s6.e2" text="abciximab" /><entity charOffset="126-135" id="DDI-PubMed.12064567.s6.e3" text="tirofiban" /><entity charOffset="140-152" id="DDI-PubMed.12064567.s6.e4" text="eptifibatide" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e0" e2="DDI-PubMed.12064567.s6.e0" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e0" e2="DDI-PubMed.12064567.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e0" e2="DDI-PubMed.12064567.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e0" e2="DDI-PubMed.12064567.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e0" e2="DDI-PubMed.12064567.s6.e4" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e1" e2="DDI-PubMed.12064567.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e1" e2="DDI-PubMed.12064567.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e1" e2="DDI-PubMed.12064567.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e1" e2="DDI-PubMed.12064567.s6.e4" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e2" e2="DDI-PubMed.12064567.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e2" e2="DDI-PubMed.12064567.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e2" e2="DDI-PubMed.12064567.s6.e4" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e3" e2="DDI-PubMed.12064567.s6.e3" /><pair ddi="false" e1="DDI-PubMed.12064567.s6.e3" e2="DDI-PubMed.12064567.s6.e4" /></sentence><sentence text=" Bivalirudin is well tolerated by patients who previously received low-molecular-weight heparin (LMWH), when LMWH is discontinued 8-14 hours before bivalirudin is started"><entity charOffset="1-12" id="DDI-PubMed.12064567.s7.e0" text="Bivalirudin" /><entity charOffset="148-159" id="DDI-PubMed.12064567.s7.e1" text="bivalirudin" /><pair ddi="false" e1="DDI-PubMed.12064567.s7.e0" e2="DDI-PubMed.12064567.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12064567.s7.e0" e2="DDI-PubMed.12064567.s7.e1" /></sentence><sentence text=" Similarly, switching from heparin to bivalirudin at the time of PCI reduces both ischemic and bleeding events"><entity charOffset="38-49" id="DDI-PubMed.12064567.s8.e0" text="bivalirudin" /></sentence><sentence text="" /></document>